{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:32:54Z","timestamp":1784986374410,"version":"3.55.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH\/NHLBI","award":["5K08HL127187"],"award-info":[{"award-number":["5K08HL127187"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.beha.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T08:55:27Z","timestamp":1549788927000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stem cell damage after chemotherapy- can we do better?"],"prefix":"10.1016","volume":"32","author":[{"given":"Joy","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Sue","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/10428190701769657","article-title":"Influence of DNA damage and repair upon the risk of treatment related leukemia","volume":"49","author":"Guillem","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1568-7864(03)00020-X","article-title":"Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome","volume":"2","author":"Casorelli","year":"2003","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"31","key":"10.1016\/j.beha.2019.02.001_bib4","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish acute Leukemia registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.beha.2019.02.001_bib6","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bmt.2015.338","article-title":"Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation","volume":"51","author":"Finke","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/10428194.2011.603445","article-title":"Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant","volume":"53","author":"Spina","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.beha.2019.02.001_bib9","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2019.02.001_bib10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2019.02.001_bib11","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/ijerph9082636","article-title":"DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias","volume":"9","author":"Casorelli","year":"2012","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/leu.2016.342","article-title":"Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants","volume":"31","author":"Pastor","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.02.001_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/asheducation-2011.1.84","article-title":"Classification of childhood aplastic anemia and myelodysplastic syndrome","volume":"2011","author":"Niemeyer","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2019.02.001_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.beha.2019.02.001_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.beha.2019.02.001_bib18","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1038\/bcj.2015.44","article-title":"Fanconi anemia gene variants in therapy-related myeloid neoplasms","volume":"5","author":"Voso","year":"2015","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.beha.2019.02.001_bib19","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib20","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2019.02.001_bib21","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood-2017-09-805879","article-title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT","volume":"131","author":"Berger","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib22","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2002-10-3035","article-title":"Repopulating defect of mismatch repair-deficient hematopoietic stem cells","volume":"102","author":"Reese","year":"2003","journal-title":"Blood"},{"issue":"7540","key":"10.1016\/j.beha.2019.02.001_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2019.02.001_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/neuonc\/not036","article-title":"Secondary hematological malignancies associated with temozolomide in patients with glioma","volume":"15","author":"Momota","year":"2013","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3892\/ol.2016.4591","article-title":"Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia","volume":"12","author":"ESS","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.beha.2019.02.001_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/nyas.12362","article-title":"The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment","volume":"1310","author":"Greim","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"19","key":"10.1016\/j.beha.2019.02.001_bib30","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.2011.41.1215","article-title":"Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms","volume":"30","author":"Larson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib32","first-page":"1975","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series","volume":"7","author":"Pedersen-Bjergaard","year":"1993","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib33","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.beha.2019.02.001_bib34","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00282-999-0195-3","article-title":"Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report","volume":"41","author":"Turker","year":"1999","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/j.beha.2019.02.001_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2015.05.045","article-title":"Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice","volume":"87","author":"Xu","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/09553002.2017.1287454","article-title":"Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications","volume":"93","author":"Miousse","year":"2017","journal-title":"Int J Radiat Biol"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccr.2011.09.011","article-title":"Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia\/acute myeloid leukemia and identifies patients at risk","volume":"20","author":"Li","year":"2011","journal-title":"Cancer Cell"},{"issue":"7483","key":"10.1016\/j.beha.2019.02.001_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.beha.2019.02.001_bib41","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1242\/dev.02568","article-title":"The journey of developing hematopoietic stem cells","volume":"133","author":"Mikkola","year":"2006","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2016.03.015","article-title":"Core circadian clock genes regulate leukemia stem cells in AML","volume":"165","author":"Puram","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.immuni.2012.05.021","article-title":"Adrenergic nerves govern circadian leukocyte recruitment to tissues","volume":"37","author":"Scheiermann","year":"2012","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.beha.2019.02.001_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOH.0b013e32832bd0f5","article-title":"Circadian rhythms influence hematopoietic stem cells","volume":"16","author":"Mendez-Ferrer","year":"2009","journal-title":"Curr Opin Hematol"},{"issue":"7186","key":"10.1016\/j.beha.2019.02.001_bib45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nature06685","article-title":"Haematopoietic stem cell release is regulated by circadian oscillations","volume":"452","author":"Mendez-Ferrer","year":"2008","journal-title":"Nature"},{"issue":"7473","key":"10.1016\/j.beha.2019.02.001_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nature12612","article-title":"Arteriolar niches maintain haematopoietic stem cell quiescence","volume":"502","author":"Kunisaki","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-014-1580-4","article-title":"Influences of vascular niches on hematopoietic stem cell fate","volume":"99","author":"Kunisaki","year":"2014","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib48","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/s41467-018-04726-3","article-title":"Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow","volume":"9","author":"Xu","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.beha.2019.02.001_bib49","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nm.3647","article-title":"Hematopoietic stem cell niche maintenance during homeostasis and regeneration","volume":"20","author":"Mendelson","year":"2014","journal-title":"Nat Med"},{"issue":"7290","key":"10.1016\/j.beha.2019.02.001_bib50","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib51","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2016-11-696070","article-title":"The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications","volume":"129","author":"Medyouf","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.stem.2013.06.015","article-title":"Regional localization within the bone marrow influences the functional capacity of human HSCs","volume":"13","author":"Guezguez","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib53","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41591-018-0030-x","article-title":"Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche","volume":"24","author":"Maryanovich","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/scrt180","article-title":"Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization","volume":"4","author":"Shi","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.beha.2019.02.001_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.exphem.2017.08.003","article-title":"The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression","volume":"55","author":"Li","year":"2017","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib56","first-page":"38","article-title":"Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: a possible mechanism for the origin of leukemia in donor cells","volume":"3","author":"Dickson","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"1","key":"10.1016\/j.beha.2019.02.001_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/bmt.2013.127","article-title":"Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source","volume":"49","author":"Shiozaki","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2019.02.001_bib58","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3324\/haematol.2011.057489","article-title":"Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome","volume":"97","author":"Donadieu","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.beha.2019.02.001_bib60","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3324\/haematol.2015.131573","article-title":"Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes","volume":"100","author":"Zambetti","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2019.02.001_bib61","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood-2006-03-007112","article-title":"Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential","volume":"110","author":"Rawls","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib62","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1182\/blood-2008-03-148999","article-title":"Defective Notch activation in microenvironment leads to myeloproliferative disease","volume":"112","author":"Kim","year":"2008","journal-title":"Blood"},{"issue":"7487","key":"10.1016\/j.beha.2019.02.001_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/bloodadvances.2017013599","article-title":"Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm","volume":"2","author":"Xiao","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2019.02.001_bib65","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.leu.2402220","article-title":"Prognostic evaluation of the microvascular network in myelodysplastic syndromes","volume":"15","author":"Korkolopoulou","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib66","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06539.x","article-title":"Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia","volume":"137","author":"Keith","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2019.02.001_bib67","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padro","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2019.02.001_bib68","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.exphem.2014.08.003","article-title":"Activation of the vascular niche supports leukemic progression and resistance to chemotherapy","volume":"42","author":"Poulos","year":"2014","journal-title":"Exp Hematol"},{"issue":"17","key":"10.1016\/j.beha.2019.02.001_bib69","doi-asserted-by":"crossref","first-page":"24455","DOI":"10.18632\/oncotarget.8227","article-title":"Neuropathy correlated with imbalanced Foxp3\/IL-17 in bone marrow microenvironment of patients with acute myeloid leukemia","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"7512","key":"10.1016\/j.beha.2019.02.001_bib70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2019.02.001_bib71","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.celrep.2013.07.048","article-title":"Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis","volume":"4","author":"Poulos","year":"2013","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.stem.2009.01.006","article-title":"Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells","volume":"4","author":"Hooper","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI79328","article-title":"Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells","volume":"125","author":"Gori","year":"2015","journal-title":"J Clin Invest"},{"issue":"11\u201312","key":"10.1016\/j.beha.2019.02.001_bib74","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1111\/j.1582-4934.2008.00521.x","article-title":"Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation","volume":"13","author":"Tjwa","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib75","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/jcp.21897","article-title":"Contribution of the fibrinolytic pathway to hematopoietic regeneration","volume":"221","author":"Heissig","year":"2009","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib76","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.stem.2007.10.012","article-title":"The plasminogen fibrinolytic pathway is required for hematopoietic regeneration","volume":"1","author":"Heissig","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.beha.2019.02.001_bib77","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm.2813","article-title":"Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity","volume":"18","author":"Geiger","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib78","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.devcel.2013.06.017","article-title":"Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration","volume":"26","author":"Nolan","year":"2013","journal-title":"Dev Cell"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib79","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nm.3155","article-title":"Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration","volume":"19","author":"Lucas","year":"2013","journal-title":"Nat Med"},{"issue":"5S","key":"10.1016\/j.beha.2019.02.001_bib80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","article-title":"NCCN guidelines updates: breast cancer","volume":"16","author":"Giordano","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.beha.2019.02.001_bib81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.6004\/jnccn.2018.0012","article-title":"Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gradishar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beha.2019.02.001_bib83","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","article-title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","volume":"132","author":"Russell","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2019.02.001_bib84","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2019.02.001_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2016.12.007","article-title":"Front-line treatment of CLL in the era of novel agents","volume":"53","author":"Robak","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.beha.2019.02.001_bib86","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","article-title":"High-dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.001_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.beha.2019.02.001_bib88","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.beha.2019.02.001_bib89","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/onc.2013.81","article-title":"Low-dose arsenic induces chemotherapy protection via p53\/NF-kappaB-mediated metabolic regulation","volume":"33","author":"Ganapathy","year":"2014","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.beha.2019.02.001_bib90","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.beha.2019.02.001_bib91","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:04:45Z","timestamp":1761498285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1521692619300040"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem cell damage after chemotherapy- can we do better?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}